Search This Blog

Tuesday, November 5, 2019

Supernus Pharmaceuticals EPS misses by $0.08, misses on revenue

Supernus Pharmaceuticals (NASDAQ:SUPN): Q3 GAAP EPS of $0.54 misses by $0.08.
Revenue of $102.14M (-0.8% Y/Y) misses by $6.56M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)